Prostaglandins are anticancer agents known to inhibit tumor cell proliferation both in vitro and in vivo by affecting the mRNA stability. Here we report that a MAR-binding protein SMAR1 is a target of Prostaglandin A2 (PGA2) induced growth arrest. We identify a regulatory mechanism leading to stabilization of SMAR1 transcript. Our results show that a minor stem and loop structure present in the 5' UTR of SMAR1 (r1-UTR) is critical for nucleoprotein complex formation that leads to SMAR1 stabilization in response to PGA2. This results in an increased SMAR1 transcript and altered protein levels, that in turn causes downregulation of Cyclin D1 gene, essential for G1/S phase transition. We also provide evidence for the presence of a variant 5' UTR SMAR1 (r17-UTR) in breast cancer-derived cell lines. This form lacks the minor stem and loop structure required for mRNA stabilization in response to PGA2. As a consequence of this, there is a low level of endogenous tumor suppressor protein SMAR1 in breast cancer-derived cell lines. Our studies provide a mechanistic insight into the regulation of tumor suppressor protein SMAR1 by a cancer therapeutic PGA2, that leads to repression of Cyclin D1 gene.
INTRODUCTION
Most of the cellular transformation processes often involve changes in the gene expression levels rather than changes in the sequence itself. The multiple layers of control include a closely knit transcriptional program and the associated translation of the product. Posttranscriptional regulation (includes mRNA stability and translation) is one such mechanism whereby the organisms control the flow of genetic information into the proteome (1) . Within the continuum of posttranscriptional regulation, mRNA stability is considered a major effector of gene regulation (2) . For example, the levels of several cell cycle regulatory molecules like Cyclin D1, p21, p27 and cdks are known to oscillate from a high in dividing cells to a low in quiescent cells. Most of these oscillations are due to transcriptional control and regulated protein stability (3) . The manifestation of cancer is a consequence of the loss of control of one or more of these regulations that leads to a loss of gene function. Anticancer drugs like flavopiridol and cyclopentenone prostaglandins (PGs) are potent inhibitors of cell cycle in various cell lines (4) (5) (6) . These compounds cause growth arrest in cultured cells and exhibit antitumor activity in vivo primarily by affecting cell cycle regulatory molecules. Cyclopentenone PGA1 and flavopiridol are shown to affect the transcriptional rate of Cyclin D1 and levels of cdk4 (7, 8) . PGA2-mediated growth inhibition is attributed to the downregulation of Cyclin D1 by reduction in the mRNA transcript. Further, microarraybased studies have led to the identification of mRNA species whose transcription and/or steady-state levels are regulated by cyclopentenone PGs (9) (10) (11) . A number of reports have also documented the role of some RNAbinding proteins such as ELAV family proteins or TIA-1 and TIAR that bind to the 5 0 or 3 0 UTR of cell cycle regulatory molecules and lead to an increased/decreased mRNA expression upon PGA2 treatment (12, 13) .
Recently, we have reported that SMAR1 (Scaffold/ Matrix attachment region-binding protein 1) is a tumor suppressor MAR-binding protein that downregulates Cyclin D1 expression by recruiting HDAC1-mSin3A co-repressor complex at Cyclin D1 promoter locus (14) . SMAR1 is documented to be a tumor suppressor protein that interacts with p53 (15) and retards B16F-10-induced melanoma in mouse model (16) . It also acts as a transcriptional repressor for MARb-mediated transcription from Eb locus, governing V(D)J recombination in T cells. Transgenic mice overexpressing SMAR1 exhibits lymphoid organomegaly, associated with higher infiltration of lymphoid cells (17) . Further, a drastic downregulation of SMAR1 in higher grades of breast cancer and cancerderived cell lines like MCF-7, HBL-100, ZR 75.3 and ZR 75.1 has also been observed. (14, 18) .
In the present study, we looked for a possible reason for downregulation of SMAR1 in breast cancer-derived cell lines and a therapeutic agent to restore SMAR1 levels. We find that the stability of SMAR1 mRNA in MCF-7 cells is low and treatment of this cell line with antitumor agent PGA2 increases the stability of the transcript. The increase in SMAR1 mRNA stability is attributed to a 18 bp stem and loop structure of SMAR1 5 0 UTR (f1-UTR) that serves as a cognition site for binding of regulatory proteins, essential for conferring transcript stability. Interestingly, we identify a variant of SMAR1 5 0 UTR (f17-UTR) that lacks the stem and loop structure of f1, leading to an altered stability. Moreover, we find that the expression of f17-UTR, correlated to an elevated Cyclin D1 level marks the malignant nature of these breast cancer-derived cell lines. Additionally, the involvement of SMAR1 in PGA2-mediated growth arrest underscores the importance of regulation of such tumor suppressor genes by anticancer agents like PGA2.
MATERIALS AND METHODS

Cell culture and transient transfections
MCF-7 cells were maintained in DMEM supplemented with 10% fetal calf serum (Invitrogen) in presence of 5% CO 2 at 378C. Cells were seeded at a density of 1 Â 10 6 per 35 mm dish and cultured for 24 h before transfection. MCF-7 cells were treated with PGA2 at various concentrations in fresh complete medium. Cells were harvested 24 h after PGA2 treatment. Actinomycin D (Sigma) was used at a concentration of 4 mg/ml and incubated for indicated time points.
Semi-quantitative RT-PCR
Seven micrograms of total RNA was subjected to reverse transcription in 20 ml reaction mixture containing 1Â random hexanucleotide mix, 1 mM dNTPs, RNase inhibitor and MuMLV reverse transcriptase (Invitrogen). PCR reactions were carried out in a 25 ml reaction mixture using 1 ml cDNA as template. Gene-specific primers used are listed in Table 1 .
Real Time RT-PCR
The quantitative measurements of RNA transcripts was performed by icycler iQ thermal cycler system (BioRad) using double-stranded DNA-specific flurophore SYBR Green. In a 25 ml PCR reaction, 1 ml of cDNA was amplified using 1Â iQ SYBR Green Supermix (BioRad) containing 0.4 mM dNTP mix, 1.5 mM MgCl2, 50 pmol of forward and reverse primer mix, SYBR Green I, 0.5 U iTaq DNA polymerase. Resolution of the product of interest from nonspecific amplification was achieved by melt curve analysis. Quantitation was done with three different sets of cDNA samples. Sigma plot was used for statistical analysis and plotting graphs.
Cloning of r1 and r17 UTR
The f1 and f17 UTRs were PCR amplified using specific primers from f1 and f17 templates, described previously (19) . The PCR products were then cloned in and PGEM-T Easy for f1 and TOPO-TA vector for f17. Plasmids isolated from positive colonies were digested with EcoR1 and cloned in pEGFP vector.
RNase protection assay (RPA)
To determine the half-life of SMAR1, Actinomycin D at a final concentration of 4 mg/ml was added to MCF-7 cells. For stability assays, PGA2 (70 mM) and Actinomycin D were added simultaneously to the culture media. Cells were harvested at different time points posttreatment, washed in 1Â PBS and pelleted at 1000 r.p.m. Total RNA was isolated using Tri-Reagent (Sigma) and used for protection assay. Antisense RNA probes were made by linearizing f1 and f17 SMAR1 templates using Nco1 or Pst1, respectively and performing in vitro transcription in the presence of SP6 or T7 RNA polymerase, respectively. In a 25 ml transcription reaction containing 1 mg of linearized DNA fragment, 1Â transcription buffer (Stratagene), 0.4 mM each of ATP, CTP, GTP, 0.25 mM UTP and 50 mCi [a32p] UTP (BRIT), 40 U of RNasin and 20 U of T7/SP6 RNA polymerase (Stratagene) were used to label RNA. Labeled RNA transcripts were then purified using probe quant G-50 columns (Amersham Pharmacia). Samples were heated at 908C for 3 min before hybridization. For the hybridization reaction, 10 mg of total RNA was incubated with labeled probe ($10 5 c.p.m.) in hybridization buffer at 378C for 16 h. The reaction mixtures were then diluted using 300 ml of digestion buffer. Single-stranded RNA was then digested using RNaseT1 (15 mg/ml) and RNaseA (1 mg/ ml) for 2 h at 308C. After phenol/chloroform extraction and ethanol precipitation, samples were analyzed on 6-10% urea gel. Band intensities were quantified using phosphorimager (BioRad).
RNA electrophoretic mobility shift assays (EMSAs)
PBK-CMV f1 and f17 were linearized with Xho1 and in vitro transcribed with T3 polymerase to yield the respective 5 0 UTR probes. The wild-type and mutant UTR minor stem and loop sequences were synthesized as forward and reverse complementary oligonuceotides (Genomechanix), containing T3 polymerase site. They were then annealed with respective pairs and in vitro transcibed with T3 polymerase to yield the probes. The sequences are: SL1-Fwd: CGAAATTAACCCTCACTAAAGGGAACC CACGGTCGACAGAAACC, Mutant 1-Fwd: CGAAATTAACCCTCACTAAAGGG AACCACACGGTCGACAGTGACC, Mutant 2-Fwd: CGAAATTAACCCTCACTAAAGG GAACCACATAATCGACAGGGACC and their reverse complementary. EMSAs were performed in a 10 ml binding reaction containing 10 mg of MCF-7 cell extract, either untreated or treated with PGA2 and 12 fmol of transcript, 10 mM Tris (pH 7.4), 15 mM KCl, 5 mM MgCl 2 and 10% glycerol. For competition assays, cold competitors were mixed with the hot probe 10 min prior to incubation with lysate. All reactions were carried out on ice for 20 min and then run on 8% native gel, resolved, dried and processed for autoradiography.
Immunoblotting and antibodies
Cells were scraped in 1Â PBS, collected at various time points and lyzed using DIGNAM buffer. Equal amount of proteins were taken for immunoblotting. Following SDS-PAGE, the resolved proteins were transferred to PVDF membrane (Amersham). Blocking was carried out with 5% BSA in Tris-buffered saline containing 0.1% Tween-20 (TBST). The membranes were probed with primary and respective secondary antibody. Proteins were detected using ECL plus chemiluminescence substrate (Amersham). Antibodies used are Cyclin D1 and Actin (Santa Cruz). SMAR1 polyclonal antibody was raised in house as described earlier (14) . Mouse secondary HRP and rabbit secondary HRP were purchased from BioRad.
Immunostaining MCF-7 cells were seeded on cover slips and after 24 h, the cells were treated with indicated amount of PGA2. Posttreatment, cells were washed with ice-cold 1Â PBS and the cells were fixed with 2% PFA for 15 min at room temperature. After subsequent quenching and blocking in PBS containing 10% FCS, SMAR1 antibody was added onto the cover slips and incubated for an hour. After three washes with cold PBS, cells were incubated with secondary rabbit FITC in dark for 45 min. Cells were then washed three times with ice-cold PBS and mounted using Antifade (DABCO) from Sigma. The mounted slides were then visualized using confocal laser microscope (LSM-510, Zeiss, Thornwood, NY).
Luciferase reporter assay
For luciferase assays, 1 mg of Cyclin D1 luciferase promoter construct (CD1) was cotransfected with f1 or f17 SMAR1 with an internal GFP control in MCF-7 cells. Luciferase assays were performed 24 h posttransfection or PGA2 treatment. For SMAR1 knockdown experiments, 100 nM siRNA was cotransfected with Cyclin D1 promoter construct. Luciferase activity was measured using Luclite substrate (Perkin Elmer, USA) and assay performed using Top-Count luminometer (Packard Life sciences, USA). Equal amounts of protein were used for luciferase assays and relative light units plotted for luciferase activity.
Chromatin Immunoprecipitation (ChIP) analysis
ChIP assay kit (Upstate Biotechnology) was performed following manufacturer's instructions. 1 Â 10 6 cells were plated per 30 mm dish and treated with PGA2 or vehicle. After treatment, DNA-protein complexes were fixed with 1% formaldehyde at 378C for 10 min at various time points. ChIP assays were carried out using anti-SMAR1, anti-HDAC1, anti-H3K9, anti-H4K10, RNA pol II, H3 pSer10 and H3K9 methyl antibodies (Cell Signaling). Input DNA, rabbit IgG (r-IgG), and mouse IgG (m-IgG) pulled DNA served as controls for all the experiments. Immunoprecipitated DNA was then subjected to 28 cycles of PCR using primers for probe II described earlier (14) .
Cell cycle analysis
MCF-7 cells were plated at a density of 1 Â 10 5 on a 35 mm dish. After 6 h of serum starvation, synchronized cells were transfected with SMAR1 siRNA, f1 or f17 SMAR1 plasmid constructs using Lipofectamine 2000 (Invitrogen). Twelve hours posttransfection, cells were treated with 30 and 70 mM PGA2 in case of siRNA transfection and cells were harvested 36 h posttransfection. After trypsinization, cells were collected and washed in PBS and pelleted at 1000 r.p.m. The resulting pellet was then re-suspended in 0.2 ml 1Â PBS containing 2% fetal bovine serum and fixed in 0.8 ml 70% ethanol. Cells were kept in the fixative for 2 h and then centrifuged for 5 min at 1000 r.p.m. Cells were then treated with RNase A (75 U/ml) and re-suspended in 0.5 ml PBS containing 50 mg/ml propidium iodide (PI) and 0.1% Triton X-100. This was incubated at room temperature for 30 min and subjected to flow cytometry. PI-stained cells were analyzed for cell cycle profiles by FACS Vantage (Becton Dickinson) using Cell Quest.
RESULTS
PGA2 induces SMAR1 expression
The negative regulation of Cyclin D1 by SMAR1 and PGA2 are well documented, though the mechanisms reported are different (8, 14) . This prompted us to check the interdependence of these pathways and look for a possible regulation of SMAR1 by PGA2. To evaluate this study, we employed MCF-7 cell line derived from mammary epithelia that is characterized by low invasive potential and induced Cyclin D1 level correlated to reduced SMAR1 expression (14) . MCF-7 cells were treated either with vehicle (ethanol) or PGA2 (0-100 mM).
Total RNA was isolated 24 h posttreatment and the cDNA obtained was subjected to RT-PCR and Real time RT-PCR analysis. SMAR1 transcript levels increased upto 45 mM PGA2 treatment, after which a steadystate level of the transcript was observed ( Figure 1A ). Quantitation by Real time RT-PCR showed that SMAR1 transcript increased 1.8-to 2-fold at 30-100 mM PGA2 ( Figure 1B ). The transcript profile was normalized using b-actin. PGA2-induced SMAR1 protein levels were checked using western blot analysis using 30 and 70 mM PGA2. At these concentrations, the protein expression increased by 3.8-and 4.5-fold respectively, while the protein levels were very low in untreated and vehicletreated cells ( Figure 1C and D). The steady increase in the protein amounts were then visualized using confocal microscopy. MCF-7 cells were treated with PGA2 (15, 30 and 70 mM) and the protein levels were monitored using SMAR1 antibody. A steady increase in the amount of SMAR1 was observed from 15 to 70 mM PGA2 concentrations ( Figure 1E ).
PGA2 stabilizes SMAR1 mRNA
It is well known that most of the reported prostaglandinmediated effects occur through alteration in mRNA halflife. Results from the previous section show that PGA2 Interestingly, upon addition of Actinomycin D and PGA2, we observe that the levels of SMAR1 transcript remained steady till 24 h ( Figure 2B , upper panel). This indicates that PGA2 stabilizes SMAR1 mRNA and maintains the steady-state levels of the transcript. The mRNA available at the given time points were normalized to the actin transcript and quantification represented as bar graph (Figure 2A and B).
SMAR1 has two 5' UTR variants in MCF-7 cells
The stability and translation of most of the transcripts are associated with the untranslated regions, both at 5 0 and 3 0 UTRs. Primers were designed to amplify the sequence from the start of exon1 and a part of exon 2 that was expected to yield an intact SMAR1 5 0 UTR of 142 bp (18) . The amplimer of 5 0 UTR from the cDNA of MCF-7 cells untreated and treated with PGA2 were checked on a 10% polyacrylamide gel. Interestingly, untreated cells showed a single amplimer ( Figure 2C , lane 1) while in case of PGA2 treatment (30 and 70 mM), there was an additional amplimer ( Figure 2C, lanes 2 and 3) . The fast migrating amplimer (lower band) was common to both untreated and PGA2 treated cells, while there was an induction of the slower migrating amplimer (upper band) specifically in PGA2-treated cells. Thus, the upper and the lower bands represent two variants of 5 0 UTR. Earlier, we have reported the identification of three clones of SMAR1 from mouse thymocyte cDNA library (19) . Out of these, two clones shared the same open reading frame and same translational reading frame of downstream sequence, but differed only by 18 bases in 5 0 UTR. The two clones were denoted as f1 (containing full-length 5 0 UTR) and f17 (containing variant 5 0 UTR lacking 18 bases). When checked using f1 and f17 template controls ( Figure 2D , lanes 2 and 4), we find that the size of upper band obtained upon PGA2 treatment corresponded to the f1 form (the upper band in Figure 2C , lanes 2 and 3; Figure 2D , lane 5) and the lower band in untreated and PGA2-treated cells corresponds to f17 form (the lower band in Figure 2C , lanes 1-3, Figure 2D , lane3). This was further verified by cloning the corresponding PCR products in PGEMT-Easy vector and DNA sequencing. RT-PCR analysis of cDNA from MCF-7 cells (untreated or treated with 70 mM PGA2, lanes 1 and 2, respectively) with primers specific for f1-UTR and f17-UTR forms was performed. The results revealed that upon PGA2 treatment there was no apparent change in the f17 form but there was an increase in the f1 form of SMAR1 (Supplementary Figure S1A) . The map of SMAR1 gene and the primers used are depicted in Supplementary Figure S1B.
The responsiveness of 5' UTR to PGA2 is essential for SMAR1 mRNA stability Next we checked if the responsiveness of SMAR1 UTR to PGA2 contributed to the stability of SMAR1 transcript. The antisense UTR transcript specific to each form was hybridized with the total RNA from MCF-7 cells untreated or treated with PGA2, as described in 'Materials and Methods' section. Protected bands revealed that the f17 form was predominant in untreated cells, unlike the f1 form (almost 3-4-times lower than f17, verified by densitometry). An increase in protection of f1 transcript was observed upon PGA2 treatment while f17 form remained almost unchanged (Supplementary Figure S1C) . To validate the transcript profiles of f1-UTR and f17-UTR containing SMAR1, cDNA obtained was subjected to Real time RT-PCR analysis using primers specific to the UTRs and melt curve analysis performed. The transcript profile obtained after Actinomycin D treatment showed that the half-life of f1 was 4-6 h while that of f17 varied between 14-16 h ( Figure 2E) . Though the transcript level of f1 remained stable after PGA2 and Actinomycin D treatment, f17 transcript levels started to decline from 12 h, as verified by melt curve analysis ( Figure 2F ). Quantification of transcripts revealed that f1-SMAR1 level increased 2-fold at 6 h time point of PGA2 treatment and remained steady till 24 h, while there was a negligible change in f17-SMAR1 level ( Figure 2G ). These results point out at the early response of f1-UTR to PGA2 treatment that stabilizes the transcript till 24 h. To further assess the response of the two UTRs to PGA2, we performed reporter assays, where the UTRs from both forms were cloned upstream of gfp gene in pEGFP vector. In case of f1-UTR transfection, we observed a 2-3-fold increase in GFP expression upon PGA2 treatment compared to the untreated cells ( Figure 2H, lanes 3-5) . f17-UTR transfection however showed only a minor change in the basal expression of GFP, showing that f1 and not f17 is responsive to PGA2 ( Figure 2H, lanes 7-9) . Thus, we demonstrate that in MCF-7 cells, f1 form of SMAR1 and not f17 form responds to PGA2. r1-UTR stem and loop structure is critical for PGA2-induced complex formation
The natural tendency of RNA is to form highly stable secondary and tertiary structures and the alteration in these structures represent a well-known regulatory mechanism for many cellular processes (20) . To determine the differences in the secondary structure that could implicate a functional significance, we analyzed the f1 and f17 UTR sequences as shown in Figure 3A . Prediction of the secondary structures of the two UTRs was done using M-fold secondary structure prediction software (21) . After energy minimizations, we observed that f17-UTR lacks a small stem and loop structure, pertaining to those missing 18 bases ( Figure 3B ). The major factor that controls mRNA turnover is the association of RNA-binding proteins with sequences forming stable secondary structures. We checked for the association of such proteins with SMAR1 UTR, in the presence and absence of PGA2. RNA EMSA were performed to check for putative nucleoprotein complex formation on f1-UTR. Labeled RNA obtained by transcription of the respective 5 0 UTR templates (f1 and f17) were used to perform EMSAs. The binding reactions were performed as described in 'Materials and Methods' section. The mixture was then run on 6% native gel and subjected to autoradiography. We could detect three specific nucleoprotein complexes on f1-UTR, in the PGA2-treated lane alone compared to the untreated cell lysate ( Figure 4A, lanes 2 and 3) . Upon addition of 50-fold molar excess self-cold competitor, we find a complete abolishment of all three shifted complexes, revealing the specificity of the complex formation ( Figure 4A, lane 4) . f17-UTR however failed to form nucleoprotein complex, indicating that the missing 18 bases holds the key determinant to bind to certain factors that in turn govern the stability and translation of SMAR1 ( Figure 4B ). To validate this, RNA was transcribed from the f1 template encoding the stem and loop structure (named SL1 hereafter). Using this transcript as probe, EMSAs were performed as described earlier. SL1 also showed nucleoprotein complex formation, comparable to the f1-UTR upon PGA2 treatment ( Figure 4D ). Further, competition experiments with 10-fold molar excess cold competitors showed the specificity of the complex ( Figure 4E ). To identify the importance of the secondary structure imparted by the sequence, binding assays using two mutants were performed. Mutant 2 had a minor modification of the primary sequence but the secondary structure remained largely unperturbed (where nucleotides outside boxB were modified) while in Mutant 1, the stem-loop structure pertaining to boxB was predicted to be partly disrupted ( Figure 4C) . When compared to SL1 ( Figure 4F , lane 2) both Mutant 1 and Mutant 2 showed a reduced complex formation, although to varying degrees. Mutant 1, where the core stem structure was disrupted, lacked the specific complex formation compared to Mutant 2 ( Figure 4F , lanes 4 and 6, respectively). Thus, we emphasize that the secondary structure imparted by these 18 bases to SMAR1-UTR is critical for the complex formation. Further, to identify the number and putative molecular weights of the components of specific nucleoprotein complex, UV cross-linking experiments were performed as described in 'Materials and Methods' section. The binding mixture employing SL1 from the intact UTR as probe was subjected to UV cross-linking, resolved on 10% SDS-PAGE gel followed by autoradiography. After subtraction of the molecular weight of the RNA probe ($15 kDa), we find the involvement of three specific proteins of $90, 40 and 15 kDa in forming the ribonucleoprotein complex ( Figure 4G ). Though the identity of these factors remains unknown, we believe that these factors that bind to the stem and loop structure of UTR upon PGA2 treatment could be the key in stabilizing the SMAR1 mRNA, resulting in altered protein levels.
The responsiveness of 5' UTR to PGA2 is essential for Cyclin D1 downregulation
Since SMAR1 is known to possess transcriptional regulatory functions, the implication of the responsiveness of 5 0 UTR to PGA2 in vivo was verified. The inverse correlation of Cyclin D1 downregulation and SMAR1 induction was first verified upon treatment with 30 and 70 mM PGA2 ( Figure 5A ). The results so far suggest that PGA2 treatment stabilizes f1 mRNA, the product of which results in Cyclin D1 repression. To confirm this, we performed luciferase reporter assays where Cyclin D1 regulation by f1 and PGA2 were compared. Cotransfection of 0.5 and 1 mg of f1 SMAR1 along with Cyclin D1 promoter construct (CD1-luc) revealed that f1 downregulated Cyclin D1 by 1.5-and 2.5-fold, comparable to PGA2-treated samples. Moreover, PGA2 treatment after knockdown of SMAR1 using the specific siRNA showed inefficient downregulation of Cyclin D1 ( Figure 5B ). This reveals the importance of SMAR1 produced from f1 transcript in PGA2-mediated after 16 h time point. The transcripts were normalized to b-actin control. (G) Real-time-PCR analysis of f1 and f17 transcripts in PGA2-treated MCF-7 cells reveals that the f1 form increases 1.5-2-fold between 6 and 16-h interval and thereafter remains steady till 24-h time point while f17 amount remains almost unchanged after PGA2 treatment. (H) The responsiveness of the two UTRs to PGA2 was verified using GFP reporter assay. One microgram of each of the UTR-GFP vector was transiently transfected in separate sets of experiments, cells collected 24 h posttransfection and verified for the GFP counts after addition of PGA2 (30 and 70 mM). There was a 1.8-2-fold increase in the GFP count in the f1 UTR (bars 3-5) compared to the f17 UTR (bars 7-9) that did not show any significant increase in GFP count. Lanes 6 and 10 represent vehicle controls with each of the UTR plasmids. EGFP vector and ethanol were used as controls (lanes 1 and 2) . Transfection of plasmids was verified using SMAR1 RT-PCR (right panel). The bars are a depiction of three sets of experiments and error bars denote the mean SD. repression of Cyclin D1. As discussed earlier, the recruitment of SMAR1 and the associated corepressor complex to Cyclin D1 promoter is well documented, and hence we verified if SMAR1 occupied Cyclin D1 promoter in response to PGA2 ( Figure 5C ). We observed the interaction of HDAC1 and SMAR1 upon PGA2 treatment (Supplementary Figure S2A and B) . Chromatin immunoprecipitation experiments using MCF-7 cells either untreated or treated with 70 mM PGA2 were performed. Amplification of probe II region in SMAR1 and HDAC1 immunoprecipitated from PGA2 treated cells (30 and 70 mM) showed the recruitment of SMAR1 corepressor complex on Cyclin D1 promoter ( Figure 5D , lanes 2 and 3, 9 and 10,). siRNA-treated, SMAR1-pulled chromatin was used to verify the specificity of the recruitment ( Figure 5D, lanes 6 and 7, 12 and 13) . These results are consistent with the direct recruitment of HDAC1 and SMAR1 on Cyclin D1 promoter that is responsible for the observed repressive effects. Upon over expression, SMAR1 is shown to deacetylate the histones at H3K9 and H4K8 loci that is accompanied by dephosphorylation of H3-phospho-ser 10 at Cyclin D1 promoter 3) and HDAC1 (lanes 9 and 10) on probe II region of Cyclin D1 promoter was studied upon PGA2 treatment in MCF-7 cells using antirabbit SMAR1 and antimouse HDAC1 antibody. Endogenous SMAR1 was depleted using SMAR1 siRNA and studied for recruitment of SMAR1 (lane 7) and HDAC1 (lane13) in MCF-7 cells treated with PGA2 (70 mM). Scrambled siRNA (scr) was used as negative control that did not alter SMAR1 or HDAC1 recruitment (lanes 6 and 12, respectively). Chromatin immunoprecipitation using mouse IgG, rabbit IgG or no antibody are used as negative control (lanes 15-17) . Reverse cross-linked sheared genomic DNA is used as positive control (input) for amplification (lanes 1, 5, 8, 11 and 14) . Transfection of empty vector was performed as mock control (lane 4). (E) To study the status of histone modifications at Cyclin D1 promoter upon PGA2 treatment, ChIP assays were performed using antibodies against RNA pol II, acetyl H3K9, acetyl H4K8, H3 p-ser10 and monomethyl H3K9 and in MCF-7 cells untreated (lanes 2, 5, 8, 11 and 14) or treated with 70 mM PGA2 (lanes 3, 6, 9, 12 and 15) and Probe II region of Cyclin D1 promoter was amplified from the immunoprecipitated DNA. Reverse cross-linked sheared genomic DNA is used as positive control (input) for amplification (lanes 1, 4, 7 and 10). Probe III region was used as control to verify the specificity of SMAR1 binding to the promoter region.
locus. Therefore, we checked if these modifications persist upon PGA2 treatment or if any additional histone modifications are involved in repression of Cyclin D1. We observed a decrease in acetylation at H3K9 ( Figure 5E , lanes 5 and 6), H4K8 ( Figure 5E , lanes 8 and 9) and phosphorylation of H3p-ser 10 ( Figure 5E , lanes 11 and 12) in PGA2-treated cells compared to mocktreated cells. In addition to this, H3K9 monomethylation status that is well documented to have a role in transcriptional activation was investigated. As shown in Figure 5E , lanes 14 and 15, PGA2 treatment decreased the methylation of probe II region compared to mock treatment. To establish the repression of transcription brought about by SMAR1, the recruitment of RNAP II on Cyclin D1 promoter locus was studied. Decreased amplification of probe II region in RNAP II-pulled samples compared to mock treated suggests decreased transcription from Cyclin D1 promoter locus ( Figure 5E , lanes 2 and 3). Nonspecific probe III was used as negative control (lanes 17 and 18). Mouse and rabbit IgG served as negative controls ( Figure 5D, lanes 15 and 17) .
Cell cycle arrest function of PGA2 mediated by SMAR1 depends on the 5' UTR Previous studies by Bhuyan et al. (22) showed that PGA2 exerts growth inhibitory activity in many human cell lines. Consistent with this, we found that PGA2 treatment caused G1 phase arrest by DNA content analysis using flow cytometry. We then checked if this growth inhibitory effect of PGA2 is mediated by SMAR1. Hundrednanomolar SMAR1 siRNA was transfected in MCF-7 cells and 16 h posttransfection, PGA2 was added to the culture media. Cell cycle analysis was done 24 h post-PGA2 treatment, after checking the knockdown of SMAR1 (data not shown). There was a marked shift of the cells from G1 to S and G2 phase, indicating that PGA2 was no longer able to arrest cells in G1 phase in the absence of SMAR1 ( Figure 6A ). The results so far suggest the involvement of PGA2 in stabilizing f1 SMAR1 and it is also clear that SMAR1 is required for PGA2-mediated growth arrest. This prompted us to investigate the difference in growth arrest function of SMAR1, in context of the two UTRs it can host. For this, MCF-7 cells were transiently transfected with equal amounts of f1 or f17-SMAR1 and analyzed for cell cycle progression. DNA content analysis revealed a 1.2-2.5-fold higher number of cells in G1/S phase in case of f1-SMAR1 transfection in comparison to f17-SMAR1 ( Figure 6B ). This hints that the growth inhibitory effect of PGA2 is mediated at least partially by f1-SMAR1. To check if the PGA2-mediated induction of SMAR1 specifically leads to Cyclin D1 downregulation, western blot analysis to check the status of other cyclins was performed. The results were then verified using siRNA treatment of SMAR1. The specificity of SMAR1 upregulation upon PGA2 treatment was also verified using siRNA treatment (Supplementary Figure S3A) . The status of other cyclins (Cyclin A, B and associated cyclin kinases cdks 4 and 6) was unaltered (Supplementary Figure S3B) . This result was corroborated using cDNA microarray results (Supplementary Figure S4) .
Breast cancer-derived cell lines from mammary epithelia primarily express f17 form To find out if the mechanism of downregulation of SMAR1 by altering the mRNA stability is common to breast cancer-derived cell lines, we screened for the presence of the two forms of SMAR1 UTR in ZR75-1, SKBR-3, T47D and MDA-MB-231. Different cell lines were cultured, RNA isolated and limited cycle RT-PCR analysis was performed. RT-PCR analysis showed that ZR-75-1 failed to show the product that corresponds to f1-UTR form but expresses f17-UTR only ( Figure 6C , lane 2 upper and middle panel). This was similar to MCF-7 cells where a very low amplification of f1-UTR transcript was observed ( Figure 6C , lane 6, upper and middle panel). Other cell lines like MDA-MB-231, SKBR3 and T-47D expressed the f1-UTR form predominantly and f17-UTR form to a lower extent ( Figure 6C , lanes 1, 4 and 5, upper and middle panel). HEK-293 cells, where f1 form is expressed predominantly and f17-UTR is undetectable was used as control ( Figure 6C , lane 3, upper and middle panels). The transcript profile we have obtained is in accordance with our previous result, where we have observed that ZR-75-1 and MCF-7 express very low amount of endogenous SMAR1 protein, whereas other cell lines showed a relatively high SMAR1 expression (14) . Since the UTR profile of ZR-75-1 and MCF-7 cells was similar, we checked the response of this cell line to PGA2 treatment and compared to MCF-7 cell line. Upon 30 mM PGA2 treatment, we found a significant induction of the f1-UTR form compared to the untreated cells ( Figure 6D, lanes 1 and 3, upper panel) . This was strikingly similar to MCF-7 cells where PGA2 treatment leads to induction of f1-UTR form ( Figure 6D , lanes 2 and 4, upper panel). Cyclin D1 profiles in these cell lines untreated or treated with PGA2 showed that the repression of Cyclin D1 occurred in case of PGA2-treated samples that correlate with the emergence of f1-UTR form.
DISCUSSION
The primary effect of hormonal therapeutics like PGA2 has been documented through alteration of half-life of mRNA (23, 24) . The significant role of mRNA stability in gene expression makes it an essential component in pathways whereby tissues and organs respond to stress. Several anticancer agents like PGA2 rely on their ability to alter the mRNA stability of target cell cycle regulatory molecules, to govern the cell cycle fate. The essence of mRNA stability is the balance between regulation by destabilization determinants or translational inhibitory structures that are rendered favorable for transcription upon appropriate stimuli (25) .
The current study stems from the fact that SMAR1 transcript is found to be drastically downregulated in higher grades of breast cancer and breast cancer-derived cell lines (14, 18) . Our aim was to decipher the reason for downregulation of SMAR1 in breast cancer-derived cell lines, specifically in context to MCF-7 cell line. Considering that both SMAR1 and PGA2 are documented to halt cell cycle at G1/S phase, it was an interesting possibility that PGA2 regulates SMAR1, thereby bringing about the repression of a common target gene, i.e Cyclin D1. MCF-7 cell line is characterized by low levels of SMAR1 transcript that is attributed to a half-life of 4 h, which in turn leads to a poor endogenous protein level. PGA2 treatment, however, renders the transcript stable till 24 h and elevates SMAR1 level in the cell line. Since majority of the cases involving mRNA stability rely on the ability of the UTR present on the 5 0 or 3 0 end of the transcript to respond to varying stimuli, the aim was to decipher the role of SMAR1 UTR in conferring stability to the transcript. Amplification of the 5 0 UTR end of SMAR1 lead to the identification of a variant form of SMAR1-UTR in MCF-7 cells. This has been previously identified as f17-SMAR1 and possesses the same ORF and reads out SMAR1 protein similar to the f1 clone. SMAR1 transcript profile also reveals that this form is predominant in MCF-7 cells, contributing to almost 65% of the observed total transcript (data not shown). The half-life of the transcript with respect to the two UTR forms is also different, with f1 having a half-life of 4-6 h while that of f17 is 14-16 h. Since the secondary structure of RNA is thought to play a significant role in imparting stability and hence dictating the protein translation, we analyzed the secondary structure of both the UTRs. The f1 UTR of SMAR1 is a thermodynamically stable structure and differs from its variant form (f17) in hosting a minor stem-loop structure, the one formed by the missing 18 bases. Recent studies highlight the importance of binding of regulatory proteins to different structures posed by the RNA (26) . Further investigations indicated that this sequence is critical for SMAR1 stabilization brought about by nucleoprotein complex formation on the stem-loop structure. The competition studies using different mutants showed that the secondary structure of the loop was important. It is thus possible that upon PGA2 treatment certain proteins that recognize this fold, bind to the stem and loop structure and regulate mRNA stability, resulting in increased SMAR1. This could be an alternate selection mechanism in tumor cells, whereby a variant UTR containing a transcript, encoding a tumor suppressor protein is retained for yet other unknown functions. Interestingly, we also find that the growth-inhibitory response of cells to PGA2 is in part due to the stabilization of SMAR1 mRNA by 5 0 UTR, as the knock down of SMAR1 leads to a compensation in the growth-arrest function of PGA2. Considering that we have identified a 5 0 UTR variant that is most likely a splice variant of the full-length UTR, it is tempting to hypothesize that RNA-binding factors involved in splicing regulate SMAR1 mRNA stability. This possibility cannot be ruled out as the splicing site between first and second exon junction of SMAR1 that spans 23 kb, hosts the 18 base stem-loop structure critical for SMAR1 stabilization. It is plausible that the recruitment of ribonucleoproteins like TIA-1 that aid in 5 0 UTR splicing (27) is regulated by another stabilizing factor. This is essential for splicing of the 60 bases from the 3 0 end of first exon to 5 end of the second exon, to form the composite stem-loop structure ( Figure 7A ). In breast cancer-derived cells, low level of endogenous SMAR1 and subsequently high level of Cyclin D1 leads to cell proliferation, malignant transformation, and hence neoplasia. Under conditions that favor proliferation or lead to malignant transformation, cancer cells might have evolved such strategies to downregulate tumor suppressor proteins like SMAR1, as witnessed by low levels of the protein in breast cancerderived cell lines. Treatment with anticancer therapeutics that lead to cell cycle arrest, reverse this effect and proteins like SMAR1 that downregulate proliferative genes are upregulated. It is also possible that SMAR1 transcript stabilized by PGA2 has a definitive link with the estrogen responsiveness of cell line, at earlier stages of transformation. In case of advanced cancer cases, however, this posttranscriptional control mechanism might be defective. Therefore, in spite of having f1-SMAR1 and expressing SMAR1 protein, the existence of alternative pathways that nullify the effect of SMAR1 cannot be ruled out. Thus, our studies provide a mechanism where a therapeutic agent PGA2 used to treat malignancies, alters the mRNA stability of tumor suppressor protein SMAR1, that downregulates the proliferative gene Cyclin D1.
